Mpox vaccine boosts Bavarian Nordic’s sales growth

The Danish vaccine company Bavarian Nordic achieved a revenue of 1.8 billion kroner in the third quarter, showing a 32% increase from the same quarter last year. This growth is majorly driven by the sales of its mpox vaccine, generating 788 million kroner, which is an increase of 263 million...